投资有风险，入市需谨慎。本内容不构成任何投资建议。投 资者不应以该等信息取代其独立判断或仅根据该等信息做出 决策。申万宏源对这些信息的准确性或完整性不作保证，亦 不对因使用该等信息而引发或可能引游躲损豢秃拐չ-α葛磊 III = 星期五 10月 今日申 .. 今日中签缴... 0 <1 股 大明电子 732376 团 国 申购指南 > 12.55 发行/行业市盈率 17.97/30.42 申购上限 0.95万股 发行价(元) 今日无新债 ● 免责声明 ...

Group 1: Company Overview - Taika Ying is the first company in the tire segment of the mining and construction industry to be listed on the Beijing Stock Exchange, recognized as the "first tire stock of the Beijing Stock Exchange" [2] - The company specializes in engineering radial tires and all-steel truck tires, holding a leading position in the engineering radial tire sector, ranking 3rd among Chinese brands and 8th globally in 2023 [3] - Taika Ying has established partnerships with major global and domestic construction machinery manufacturers, including SANY Group, XCMG, Liebherr, and JCB, among others [3] Group 2: Financial Performance - In 2024, Chaoying Electronics reported a main business revenue of 3.945 billion yuan, ranking 41st among global PCB manufacturers with a market share of 0.75% [5] - The company ranks 23rd among comprehensive PCB companies in China, with a market share of 1.41% in mainland China [5] - Chaoying Electronics is recognized as one of the top ten automotive electronic PCB suppliers globally and among the top five in China [5] Group 3: Market Position and Risks - Taika Ying's market share in the domestic engineering radial tire supporting market ranks 3rd among all tire brands, with the highest market share in the domestic market for large-tonnage crane tires [3] - Chaoying Electronics has a stable collaboration with Tier 1 automotive suppliers and well-known electric vehicle manufacturers like Tesla [4] - Both companies face risks related to their operational models, with Taika Ying relying on an outsourcing production model and Chaoying Electronics being sensitive to macroeconomic fluctuations and downstream market demand [4][5]

Core Viewpoint - The article discusses the recent IPO activities in the Chinese stock market, highlighting the significance of the subscription process and the expected performance of new stocks, particularly focusing on Dana Biotechnology and Zhongcheng Consulting. Group 1: IPO Performance - Dana Biotechnology's subscription is noted to be relatively easy but significant, with results expected to provide important reference for future subscriptions, especially for fractional shares [1] - Marco Polo's stock debuted with a significant opening increase of 140.73%, closing with a rise of 128.80% at 31.46 yuan, with a total trading volume of 75.7042 million shares and a turnover of 2.582 billion yuan, indicating a high turnover rate of 77.36% [1] - A single subscription for Marco Polo could yield a profit of 8,855 yuan [1] Group 2: Upcoming IPOs and Subscription Details - Dapeng Industrial, a leading manufacturer in precision cleaning equipment, is set to raise approximately 129 million yuan through its IPO [1] - Zhongcheng Consulting is expected to issue up to 14 million shares, with around 12.6 million shares available for online subscription after accounting for a 10% reduction [4] - The estimated subscription amount for Zhongcheng Consulting is projected to be between 720 billion to 730 billion yuan, indicating a high demand for shares [5] Group 3: Subscription Requirements - The top subscription limit for Zhongcheng Consulting is estimated at approximately 900.9 million yuan, with a minimum funding requirement of around 579.37 million yuan for the shares [5] - The competition for fractional shares in Zhongcheng Consulting is expected to be intense, with a minimum funding threshold likely starting at 600 million yuan, potentially reaching 650 million yuan [5]

Group 1: Company Overview - Danah Biotechnology, established on March 10, 2014, focuses on early diagnosis of invasive fungal diseases and other pathogenic microorganisms, recognized as a national high-tech enterprise and a key specialized "little giant" enterprise supported by the state [2] - The main products include diagnostic reagents and instruments, with reagents accounting for 90.52% of revenue in 2024, while instruments contribute 6.06% [2] - Danah holds a market share of approximately 30% in China's invasive fungal disease diagnostic reagent market as of 2022 [2] Group 2: Product and Supply Chain - The core raw material for Danah's main product, the (1-3)-β-D-glucan test kit, is horseshoe crab blood, which accounted for 21.34% to 32.57% of revenue from 2022 to June 2025 [3] - Horseshoe crabs are classified as a national second-level protected animal, leading to stricter regulations on their utilization, creating uncertainty regarding future supply [3] - Danah has sufficient inventory of horseshoe crab blood to meet production needs for over five years and has begun exploring overseas procurement channels [3] Group 3: Market Position and Financial Performance - Marco Polo, a leading manufacturer and seller of building ceramics, has production bases in multiple locations, with revenues of 8.661 billion, 8.925 billion, and 7.324 billion from 2022 to 2024 [4] - The company ranks first in the domestic building ceramics industry in terms of revenue from 2022 to 2024, indicating strong market presence [4] - Marco Polo's sales model includes both distribution and direct sales, with a significant portion of revenue coming from glazed tiles, which have seen an increasing trend in sales [4][6] Group 4: Revenue Trends and Risks - Marco Polo's main business revenue is projected to decline by 17.95% in 2024 compared to 2023, attributed to changing consumer preferences towards glazed tiles [6] - The company faces potential risks related to fluctuations in the real estate market, which is closely tied to its industry, as indicated by a declining real estate development prosperity index from 2022 to 2024 [6] - Marco Polo also highlights risks associated with raw material and energy price volatility, which could significantly impact profitability if costs cannot be passed on to customers [7]

Market Overview - The Shanghai Composite Index fell by 1.47% to 3839.76 points, with a weekly high of 3931.05 points [1] - The Shenzhen Component Index decreased by 4.99% to 12688.94 points, reaching a high of 13405.51 points [1] - The ChiNext Index dropped by 5.71% to 2935.37 points, with a peak of 3124.83 points [1] - In global markets, the Nasdaq Composite rose by 2.14%, the Dow Jones Industrial Average increased by 1.56%, and the S&P 500 gained 1.7% [1] - In the Asia-Pacific region, the Hang Seng Index fell by 3.97%, and the Nikkei 225 decreased by 1.05% [1] New Stock Issuance - Six new stocks were issued last week, with details provided in the table [2] Margin Trading Situation - The total margin trading balance in the Shanghai and Shenzhen markets was 24219.32 billion, with a financing balance of 24053.82 billion and a securities lending balance of 165.5 billion [3] - The margin trading balance decreased by 123.71 billion compared to the previous week [3] - The Shanghai market's margin trading balance was 12355.0 billion, down by 62.59 billion, while the Shenzhen market's balance was 11864.32 billion, down by 61.12 billion [3] - A total of 3450 stocks had financing funds buying in, with 210 stocks having buy amounts exceeding 1 billion [3] Top Margin Buying Stocks - The top three stocks by margin buying amount were: - ZTE Corporation: 138.43 billion [4] - Sungrow Power Supply: 134.01 billion [4] - Zhongji Xuchuang: 111.15 billion [4] Fund Issuance - Two new funds were issued last week, with details provided in the table [5] Share Buyback Announcements - There were 25 new share buyback announcements last week, with the top five by execution amount listed [6] - The highest execution amounts were in the electronic, pharmaceutical, and machinery equipment sectors [6]

Core Viewpoint - The article provides an overview of recent developments in the convertible bond market, including new issuances and important announcements regarding existing bonds [1][6]. Group 1: New Issuances - Jinlang will be available for subscription on October 17 [1]. - Super Electronics and Taikai Ying are also highlighted as new stock subscriptions on the Shanghai and Shenzhen exchanges and the Beijing Stock Exchange, respectively [1]. Group 2: Important Announcements - The announcement regarding the adjustment of Zhengchuan Convertible Bond was made on October 15, 2025 [1]. Group 3: Convertible Bond Data - A detailed table lists various convertible bonds, including their current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [3][5]. - For example, the current price of Jiuzhou Convertible Bond 2 is 123.799, with a strong redemption price of 102.040, and a conversion value of 125.18 [3]. - The remaining scale of Changji Convertible Bond is 4.964 billion, with a conversion value of 126.41 [3].

Group 1 - The company, Taike Ying, is set to launch its public offering with an issuance price of 7.50 yuan and an issuance price-to-earnings ratio of 11.02 times [1][2] - The total number of shares to be issued is 44.25 million, with 39.825 million shares available for online subscription and a strategic placement of 4.425 million shares, accounting for 10% of the initial offering size [1][2] - The expected total fundraising amount is 332 million yuan, primarily allocated to projects for upgrading specialized tire products, establishing an innovation technology research center, and enhancing an intelligent management system [1][2] Group 2 - The company's main business involves the design, research and development, sales, and service of tires for mining and construction [2] - Financial projections indicate net profits of 108 million yuan, 138 million yuan, and 157 million yuan for the years 2022, 2023, and 2024, respectively, reflecting year-on-year growth rates of 81%, 27.31%, and 13.58% [2] - Key financial metrics for the company show total assets of 1.646 billion yuan, net assets of 693.37 million yuan, and operating income of 2.295 billion yuan for 2024 [3]

Group 1 - The article discusses the subscription details for the stock of Marco Polo (stock code: 001386), including the issuance price of 13.75 yuan and the maximum subscription limit of 32,000 shares [1] - The article provides the earnings ratios for the issuance and industry, which are 14.27 and 32.2 respectively, indicating the valuation metrics for potential investors [1] - It mentions the convertible bond of Funi Co., with a conversion price of 9.84 yuan and a bond rating of AA+, highlighting the investment quality of the bond [1]

Core Viewpoint - The A-share market is entering a period of intensive new stock offerings, with five companies available for subscription this week from October 13 to October 17, including Marco Polo, Chao Ying Electronics, He Yuan Bio, Xi'an Yicai, and Biobetter [1] Group 1: Marco Polo - Marco Polo is one of the largest manufacturers and sellers of building ceramics in China, with major brands including "Marco Polo Tiles" and "Weimei LD Ceramics" [2] - The company has five production bases located in Dongguan, Qingyuan, Fengcheng, Chongqing, and Tennessee, USA, focusing on both glazed and unglazed tiles [2] - Projected revenues for 2022 to 2024 are 8.661 billion, 8.925 billion, and 7.324 billion yuan, with net profits of 1.514 billion, 1.353 billion, and 1.327 billion yuan respectively [2] - The funds raised will be used for various smart manufacturing upgrades and capacity enhancement projects [2] Group 2: He Yuan Bio - He Yuan Bio is an innovative biopharmaceutical company focused on original innovation, with a leading global rice recombinant protein expression system [3] - The company has developed a third-generation technology platform achieving 20-30g/kg expression levels of human albumin, with several products in various stages of clinical research [3][4] - Projected revenues for 2022 to 2024 are 13 million, 24 million, and 25 million yuan, with net losses of 144 million, 187 million, and 151 million yuan respectively [3] Group 3: Chao Ying Electronics - Chao Ying Electronics specializes in the research, production, and sales of printed circuit boards (PCBs), with applications in automotive electronics, displays, storage, and consumer electronics [5] - The company has established stable partnerships with major global automotive suppliers and display manufacturers [5][6] - Projected revenues for 2022 to 2024 are 3.514 billion, 3.656 billion, and 4.124 billion yuan, with net profits of 141 million, 266 million, and 276 million yuan respectively [6] Group 4: Xi'an Yicai - Xi'an Yicai focuses on the research, production, and sales of 12-inch silicon wafers, ranking first in mainland China and sixth globally [7] - The company has the highest number of authorized domestic and international invention patents in the 12-inch silicon wafer sector [7] - Projected revenues for 2022 to 2024 are 1.055 billion, 1.474 billion, and 2.121 billion yuan, with net losses of 412 million, 578 million, and 738 million yuan respectively [7][8] Group 5: Biobetter - Biobetter is a biopharmaceutical company focused on innovative drug development for major diseases, with several products in various stages of clinical trials [9] - The company has a core product, BEBT-908, that has been approved for market, while others are in different phases of clinical trials [9][10] - Projected net losses for 2022 to 2024 are 188 million, 173 million, and 56 million yuan respectively [10][11]

Core Viewpoint - The A-share market is entering a period of intensive new stock offerings, with five companies available for subscription this week from October 13 to October 17, including Marco Polo, Chao Ying Electronics, He Yuan Bio, Xi'an Yicai, and Biobetter [1] Group 1: Marco Polo - Marco Polo is one of the largest manufacturers and sellers of building ceramics in China, with major brands including "Marco Polo Tiles" and "Weimei L&D Ceramics" [2] - The company has five production bases located in Dongguan, Qingyuan, Fengcheng, Chongqing, and Tennessee, USA, focusing on glazed and unglazed tiles [2] - For the fiscal years 2022 to 2024, Marco Polo's revenue is projected to be 8.661 billion, 8.925 billion, and 7.324 billion yuan, with net profits of 1.514 billion, 1.353 billion, and 1.327 billion yuan respectively [2] - The funds raised will be used for various smart manufacturing upgrades and capacity enhancement projects [2] Group 2: He Yuan Bio - He Yuan Bio is an innovative biopharmaceutical company that has developed a leading rice recombinant protein expression system [3] - The company has achieved a human albumin expression level of 20-30g/kg using its OryzHiExp third-generation technology platform [3] - Revenue projections for 2022 to 2024 are 13 million, 24 million, and 25 million yuan, with net losses of 144 million, 187 million, and 151 million yuan respectively [3][4] - The raised funds will be allocated to the construction of an industrial base for recombinant human albumin and new drug development projects [4] Group 3: Chao Ying Electronics - Chao Ying Electronics specializes in the research, production, and sales of printed circuit boards (PCBs), with applications in automotive electronics, displays, storage, and consumer electronics [5] - The company has established stable partnerships with major global automotive suppliers and display panel manufacturers [6] - Revenue for 2022 to 2024 is expected to be 3.514 billion, 3.656 billion, and 4.124 billion yuan, with net profits of 141 million, 266 million, and 276 million yuan respectively [6] - The funds raised will be used for high-layer and HDI project investments and to repay bank loans [6] Group 4: Xi'an Yicai - Xi'an Yicai focuses on the research, production, and sales of 12-inch silicon wafers, ranking first in mainland China and sixth globally [7] - The company has the highest number of authorized domestic and foreign invention patents in the 12-inch silicon wafer sector in mainland China [7] - Revenue projections for 2022 to 2024 are 1.055 billion, 1.474 billion, and 2.121 billion yuan, with net losses of 412 million, 578 million, and 738 million yuan respectively [7][8] - The raised funds will be fully invested in the second phase of the Xi'an Yiswei silicon industry base project [8] Group 5: Biobetter - Biobetter is a biopharmaceutical company focused on innovative drug development for major diseases, including cancer and autoimmune diseases [9] - The company has several products in various stages of clinical trials, with its core product BEBT-908 already approved for market [9][10] - Revenue projections for 2022 to 2024 indicate net losses of 188 million, 173 million, and 56 million yuan respectively [10] - The funds raised will be used for new drug development and the establishment of a research center and formulation industrialization base [11]